Worse LV Global Longitudinal Strain for STEMI With COPD

This article originally appeared here.
Share this content:
Worse LV Global Longitudinal Strain for STEMI With COPD
Worse LV Global Longitudinal Strain for STEMI With COPD

THURSDAY, Aug. 24, 2017 (HealthDay News) -- For patients with ST-segment elevation myocardial infarction (STEMI), those with chronic obstructive pulmonary disease (COPD) have significantly more impaired left ventricular (LV) global longitudinal strain (GLS), according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Laurien Goedemans, M.D., from the Leiden University Medical Center in the Netherlands, and colleagues used advanced two-dimensional speckle tracking echocardiography to compare STEMI patients with versus without COPD in terms of infarct size and LV systolic function. A total of 1,750 patients with STEMI were enrolled, of whom 7.6 percent had COPD. Left ventricular ejection fraction (LVEF) and wall motion score index were measured; biomarkers were used to assess infarct size. LV GLS was measured with two-dimensional speckle tracking.

The researchers found that based on peak levels of creatine kinase (1,315 versus 1,477 U/L; P = 0.106) and troponin T (3.3 versus 3.9 µg/L; P = 0.489), there were no differences in infarct size. Comparable LVEF (46 versus 47 percent; P = 0.591) and wall motion score index (1.38 versus 1.38; P = 0.690) were observed. Compared to patients without COPD, patients with COPD had significantly more impaired LV GLS (−13.9 ± 3.0 percent versus 14.7 ± 3.9 percent; P = 0.034).

"Patients with COPD exhibit more impaired LV GLS on advanced echocardiography than patients without COPD, suggesting a greater functional impairment at an early stage after STEMI," the authors write.

One author and the Department of Cardiology at the Leiden University Medical Center disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »